Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma

Koirala, Pratistha, Roth, Michael E., Gill, Jonathan, Piperdi, Sajida, Chinai, Jordan M., Geller, David S., Hoang, Bang H., Park, Amy, Fremed, Michael A., Zang, Xingxing, Gorlick, Richard·2016·Scientific Reports
DOI 10.1038/srep30093

Cited by (267)

Items 101–200 of 267

  1. Immunotherapeutic Challenges for Pediatric Cancers
    Brian J. Hutzen, Mohammed G. Ghonime, Joel Lee, Elaine R. Mardis, Ruoning Wang, Dean Anthony Lee, Mitchell Stuart Cairo, Ryan David Roberts, Timothy P. Cripe, Kevin A. Cassady · 2019 · Molecular Therapy — Oncolytics
  2. Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
    Kazuhiko Hashimoto, Shunji Nishimura, Masao Akagi · 2020 · Diagnostics
  3. Immunosuppressive Tumor Microenvironment of Osteosarcoma
    Aaron Michael Taylor, Jianting Sheng, Patrick Kwok Shing Ng, Jeffrey M. Harder, Parveen Kumar, Ju Young Ahn, Yuliang Cao, Alissa M. Dzis, Nathaniel Jillette, Andrew E. Goodspeed et al. · 2025 · Cancers
  4. Clinical outcome of osteosarcoma and its correlation with programmed death-ligand 1 and T cell activation markers
    Kazushige Yoshida, Masanori Okamoto, Jun Sasaki, Chika Kuroda, Haruka Ishida, Katsuya Ueda, Satomi Okano, Hirokazu Ideta, Takayuki Kamanaka, Atsushi Sobajima et al. · 2019 · OncoTargets and Therapy
  5. Key genes with prognostic values in suppression of osteosarcoma metastasis using comprehensive analysis
    Mi Li, Xin Jin, Hao Li, Gang Wu, Shanshan Wang, Caihong Yang, Sisi Deng · 2020 · BMC Cancer
  6. Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy
    Rilan Bai, Jiuwei Cui · 2022 · Frontiers in Immunology
  7. Metastatic immune infiltrates correlate with those of the primary tumour in canine osteosarcoma
    Sita S. Withers, Daniel S. York, Jin Wook Choi, Kevin Woolard, Renée Laufer Amorim, Ellen E. Sparger, Jenna H. Burton, Stephen J. McSorley, Arta Monir Monjazeb, William J. Murphy et al. · 2019 · Veterinary and Comparative Oncology
  8. Development of a novel immune-related genes prognostic signature for osteosarcoma
    Zuolong Wu, Ya-jun Deng, Guangzhi Zhang, Enhui Ren, Wenhua Yuan, Qi-qi Xie · 2020 · Scientific Reports
  9. Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma
    Sunetra Das, Rupa Idate, Daniel P. Regan, Jared Scott Fowles, Susan E. Lana, Douglas H. Thamm, Daniel L. Gustafson, Dawn L. Duval · 2021 · Communications Biology
  10. Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial
    Palmerini, Emanuela, Lopez Pousa, Antonio, Grignani, Giovanni, Redondo, Andres, Hindi, Nadia, Provenzano, Salvatore, Sebio, Ana, Lopez Martin, Jose Antonio, Valverde, Claudia, Martinez Trufero, Javier et al. · 2025 · Cancer
  11. Prognostic significance and therapeutic potentials of immune checkpoints in osteosarcoma
    Vafa Meftahpour, Ali Aghebati‐Maleki, Ali Fotouhi, Elham Safarzadeh, Leili Aghebati Maleki · 2021 · EXCLI journal
  12. Single-cell RNA datasets and bulk RNA datasets analysis demonstrated C1Q+ tumor-associated macrophage as a major and antitumor immune cell population in osteosarcoma
    Tu, Jihao, Wang, Duo, Zheng, XiaoTian, Liu, Bin · 2023 · Frontiers in Immunology
  13. Risk score based on expression of five novel genes predicts survival in soft tissue sarcoma
    Hui-Yun Gu, Chao Zhang, Jia Guo, Min Yang, Hou-Cheng Zhong, Wei Jin, Yang Liu, Liping Gao, Renxiong Wei · 2020 · Aging
  14. Prospects for NK Cell Therapy of Sarcoma
    Mieszko Lachota, Marianna Vincenti, Magdalena Winiarska, Kjetil Boye, Radosław Zagożdżon, Karl‐Johan Malmberg · 2020 · Cancers
  15. The Sarcoma Immune Landscape: Emerging Challenges, Prognostic Significance and Prospective Impact for Immunotherapy Approaches
    Anna A. Koumarianou, José Durán · 2021 · Cancers
  16. Evaluation of HLA-G, HLA-E, and PD-L1 proteins in oral osteosarcomas
    Diego Antônio Costa Arantes, Andréia Souza Gonçalves, Bruno Correia Jham, Eliza Carla Barroso Duarte, Élbio Cândido de Paula, Henrique Moura de Paula, Elismauro Francisco Mendonça, Aline Carvalho Batista · 2016 · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology
  17. Metabolism and senescence in the immune microenvironment of osteosarcoma: focus on new therapeutic strategies
    Hui Ying, Zhiqiang Li, Meng-Pan Li, Wencai Liu · 2023 · Frontiers in Endocrinology
  18. Evidence of Interleukin 21 Reduction in Osteosarcoma Patients Due to PD-1/PD-L1-Mediated Suppression of Follicular Helper T Cell Functionality
    Wenwu Gao, Junjie Zhou, Bin Ji · 2017 · DNA and Cell Biology
  19. Focus on Hypoxia-Related Pathways in Pediatric Osteosarcomas and Their Druggability
    Marina Pierrevelcin, Quentin Fuchs, Benoît Lhermitte, Mélissa Messé, Éric Guérin, Noëlle Weingertner, Sophie Martin, Isabelle H Lelong-Rebel, Charlotte Nazon, Monique Dontenwill et al. · 2020 · Cells
  20. Cancer combination therapies by silencing of CTLA‐4, PD‐L1, and TIM3 in osteosarcoma
    Amin Daei Sorkhabi, Aila Sarkesh, Ali Fotouhi, Hossein Saeedi, Leili Aghebati Maleki · 2022 · IUBMB Life
  21. A chimeric human/dog-DNA vaccine against CSPG4 induces immunity with therapeutic potential in comparative preclinical models of osteosarcoma
    Lidia Tarone, Davide Giacobino, Mariateresa Camerino, Lorella Maniscalco, Selina Iussich, Lorenza Parisi, Giuseppe Giovannini, Alfredo Dentini, Elisabetta Bolli, Elena Quaglino et al. · 2023 · Molecular Therapy
  22. Potential role of the PD-L1 expression and tumor-infiltrating lymphocytes on neuroblastoma
    Shogo Zuo, Masayuki Sho, Toshio Sawai, Hiromichi Kanehiro, Kosaku Maeda, Makiko Yoshida, Ryo Tsukada, Motonari Nomura, Hiroomi Okuyama · 2020 · Pediatric Surgery International
  23. Natural Killer Cell Immunotherapy for Osteosarcoma
    Tullius, Brian P., Setty, Buhvana A., Lee, Dean A. · 2020 · Advances in Experimental Medicine and Biology
  24. LINC00657 knockdown suppresses hepatocellular carcinoma progression by sponging miR-424 to regulate PD-L1 expression
    Xinling Cao, Guanping Zhang, Tao Li, Chengming Zhou, Lei Bai, Jinming Zhao, T. Tursun · 2020 · Genes & Genomics
  25. Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRPα infiltration after denosumab treatment
    Yu Toda, Kenichi Kohashi, Hidetaka Yamamoto, Shin Ishihara, Yoshihiro Ito, Yosuke Susuki, Kengo Kawaguchi, Daisuke Kiyozawa, Dai Takamatsu, Izumi Kinoshita et al. · 2021 · Scientific Reports
  26. Checkpoint Immunotherapy in Pediatric Oncology: Will We Say Checkmate Soon?
    Alex Ciurej, Elizabeth C. Lewis, Avanti Gupte, Eman T. Al‐Antary · 2023 · Vaccines
  27. Thrombospondin‐1 induced programmed death‐ligand 1‐mediated immunosuppression by activating the STAT3 pathway in osteosarcoma
    Zhuochao Liu, Junxiang Wen, Fangqiong Hu, Jun Wang, Chuanzhen Hu, Weibin Zhang · 2021 · Cancer Science
  28. A TLR4 Agonist Induces Osteosarcoma Regression by Inducing an Antitumor Immune Response and Reprogramming M2 Macrophages to M1 Macrophages
    Iseulys Richert, Paul BERCHARD, Lhorra Abbes, Alexey Novikov, Kamel Chettab, Alexandra Vandermoeten, Charles Dumontet, Marie Karanian, Jérôme Kerzerho, Martine Caroff et al. · 2023 · Cancers
  29. Biomarker recommendation for PD‐1/PD‐L1 immunotherapy development in pediatric cancer based on digital image analysis of PD‐L1 and immune cells
    Manuel A. Silva, Nicolas Triltsch, S. Leis, Ivan Kanchev, Tze Heng Tan, Benjamine Van Peel, Marian Van Kerckhoven, Vanessa Deschoolmeester, Johannes Zimmermann · 2020 · The Journal of Pathology Clinical Research
  30. Prognostic Value of Programmed Cell Death 1 Ligand-1 in Patients With Bone and Soft Tissue Sarcomas: A Systemic and Comprehensive Meta-Analysis Based on 3,680 Patients
    Feng Wang, Tao Yu, Chengbin Ma, Hongmou Yuan, Haifei Zhang, Zhiyu Zhang · 2020 · Frontiers in Oncology
  31. Immune-related prognostic genes signatures in the tumor microenvironment of sarcoma
    Jun Wang, Mingzhi Gong, Zhenggang Xiong, Yangyang Zhao, Deguo Xing · 2021 · Mathematical Biosciences & Engineering
  32. Introducing Fluorescence-Guided Surgery for Pediatric Ewing, Osteo-, and Rhabdomyosarcomas: A Literature Review
    Zeger Rijs, Bernadette Jeremiasse, Naweed Shifai, Hans A. J. Gelderblom, Cornelis F.M. Sier, Alexander L. Vahrmeijer, Fijs W. B. van Leeuwen, Alida F. W. van der Steeg, Michiel A. J. van de Sande · 2021 · Biomedicines
  33. PODNL1 Methylation Serves as a Prognostic Biomarker and Associates with Immune Cell Infiltration and Immune Checkpoint Blockade Response in Lower-Grade Glioma
    Humaira Noor, Ashraf Zaman, Charles Teo, Michael Edward Sughrue · 2021 · International Journal of Molecular Sciences
  34. Extracellular Vesicles in Osteosarcoma: Antagonists or Therapeutic Agents?
    Viviana De Martino, Michela Rossi, Giulia Battafarano, Jessica Pepe, Salvatore Minisola, Andrea Del Fattore · 2021 · International Journal of Molecular Sciences
  35. Water extract of sporoderm-broken spores of Ganoderma lucidum enhanced pd-l1 antibody efficiency through downregulation and relieved complications of pd-l1 monoclonal antibody
    Jiaming He, Wenkan Zhang, Tuoyu Di, Jiahong Meng, Yiying Qi, Guoqi Li, Yuxiang Zhang, Hang Su, Weiqi Yan · 2020 · Biomedicine & Pharmacotherapy
  36. Translational cell biology of highly malignant osteosarcoma
    Albert Roessner, Christoph Hubertus Lohmann, Dörthe Jechorek · 2021 · Pathology International
  37. Extracellular Vesicle-Mediated IL-1 Signaling in Response to Doxorubicin Activates PD-L1 Expression in Osteosarcoma Models
    Su Yati, Atiruj Silathapanasakul, Chakrarin Thakaeng, Mayuree Chanasakulniyom, Napat Songtawee, Sureerut Porntadavity, Peraphan Pothacharoen, Dumnoensun Pruksakorn, Prachya Kongtawelert, Pa‐thai Yenchitsomanus et al. · 2022 · Cells
  38. Targeted transcriptional profiling of the tumor microenvironment reveals lymphocyte exclusion and vascular dysfunction in metastatic osteosarcoma
    Laurie Sorenson, Yanfen Fu, Tressa Hood, Sarah E. Warren, Troy A. McEachron · 2019 · OncoImmunology
  39. PD‑L1/PD‑1 axis serves an important role in natural killer cell‑induced cytotoxicity in osteosarcoma
    Minglei Zhang, Li Chen, Yanjiao Li, Daliang Kong · 2019 · Oncology Reports
  40. Microenvironment matters: insights from the FOSTER consortium on microenvironment-driven approaches to osteosarcoma therapy
    Aurélie Dutour, Michela Pasello, Luke Farrow, Mahetab H. Amer, Natacha Entz‐Werlé, Michaela Nathrath, Katia Scotlandi, Sibylle Mittnacht, Anne Gomez‐Brouchet · 2025 · Cancer and Metastasis Reviews
  41. First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001
    Yan Zhou, Qingcheng Yang, Yang Dong, Tong Ji, Bing Zhang, Cheng Yang, Shuier Zheng, Lina Tang, Chenliang Zhou, Guowei Qian et al. · 2022 · Clinical Cancer Research
  42. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma
    Ping Liu, Qing Xiao, Bing Rong Zhou, Zhehao Dai, Yijun Kang · 2019 · World Neurosurgery
  43. Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin
    Mohammed Faruk, Sani Ibrahim, Sirajo Mohammed Aminu, Ahmed Adamu, Adamu Abdullahi, Aishatu Maude Suleiman, Abdulmumini Hassan Rafindadi, Abdullahi Mohammed, Yawale Iliyasu, John Idoko et al. · 2021 · PLoS ONE
  44. Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force
    Sarah B. Whittle, Katharine Offer, Ryan David Roberts, Amy Kathleen LeBlanc, Cheryl A. London, Robbie G. Majzner, Alex Yee-Chen Huang, Peter J. Houghton, Alejandro Sweet-Cordero, Patrick Joseph Grohar et al. · 2021 · Pediatric Blood & Cancer
  45. NGS-analysis to the rescue: dual checkpoint inhibition in metastatic osteosarcoma – a case report and review of the literature
    Nuytemans, Laure, Sys, Gwen, Creytens, David, Lapeire, Lore · 2021 · Acta Clinica Belgica
  46. Dedifferentiated Chondrosarcoma from Molecular Pathology to Current Treatment and Clinical Trials
    Weronika Zając, Julia Dróżdż, Weronika Kisielewska, Weronika Karwowska, Monika Dudzisz‐Śledź, Agnieszka E. Zając, Aneta Maria Borkowska, Anna Szumera‐Ciećkiewicz, Bartłomiej Szostakowski, Piotr Lukasz Rutkowski et al. · 2023 · Cancers
  47. Evaluation of tumor-infiltrating lymphocytes in osteosarcomas of the jaws: a multicenter study
    Pollianna Muniz Alves, José Alcides Almeida de Arruda, Diego Antônio Costa Arantes, Sara Ferreira dos Santos Costa, Lucas Lacerda de Souza, Hélder Antônio Rebelo Pontes, Felipe Paiva Fonseca, Ricardo Alves Mesquita, Cassiano Francisco Weege Nonaka, Elismauro Francisco Mendonça et al. · 2018 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
  48. Clinicopathological evaluation of PD-L1 expression and cytotoxic T-lymphocyte infiltrates across intracranial molecular subgroups of ependymomas: are these tumors potential candidates for immune check-point blockade?
    Aruna Nambirajan, Prit Benny Malgulwar, Agrima Sharma, Meher Thej Boorgula, Ramesh Sharanappa Doddamani, Manmohan Singh, Vaishali S. Suri, Chitra Sarkar, Mehar Chand Sharma · 2019 · Brain Tumor Pathology
  49. Review of pre-metastatic niches induced by osteosarcoma-derived extracellular vesicles in lung metastasis: A potential opportunity for diagnosis and intervention
    Xia Zhongyu, Wei Xu, Zhang Hongmei, Ge Xiaodong, Yan Xiaojing, Lian Yuanpei, Li Zhu, Fan Zhenmin, Jianda Xu · 2024 · Biomedicine & Pharmacotherapy
  50. The Heterogeneity of Infiltrating Macrophages in Metastatic Osteosarcoma and Its Correlation with Immunotherapy
    Zhanchao Wang, Huiqiao Wu, Yu Chen, Huajiang Chen, Wen Yuan, Xinwei Wang · 2021 · Journal of Oncology
  51. A Review of T-Cell Related Therapy for Osteosarcoma
    Kazushige Yoshida, Masanori Okamoto, Kaoru Aoki, Jun Takahashi, Naoto Saito · 2020 · International Journal of Molecular Sciences
  52. Thermogel Delivers Oxaliplatin and Alendronate in situ for Synergistic Osteosarcoma Therapy
    Yifu Sun, Ke Li, Chen Li, Ying Zhang, Duoyi Zhao · 2020 · Frontiers in Bioengineering and Biotechnology
  53. Analysis of Immune Gene Expression Subtypes Reveals Osteosarcoma Immune Heterogeneity
    Ben Wan, Renxian Wang, Jing‐Jun Nie, Yuyang Sun, Bowen Zhang, Weifeng Liu, Dafu Chen · 2021 · Journal of Oncology
  54. Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients
    Sumi Yun, Yujun Park, Seyoung Moon, Soomin Ahn, Kyoungyul Lee, Hyo Jin Park, Hye Seung Lee, Gheeyoung Choe, Kyu Sang Lee · 2019 · Journal of Cancer
  55. Expression and Clinical Significance of Various Checkpoint Molecules in Advanced Osteosarcoma: Possibilities for Novel Immunotherapy
    Lu Xie, Chenglong Chen, Xin Liang, Jie Hua Xu, Xin Sun, Kunkun Sun, Rongli Yang, Xiaodong Tang, Wei Guo · 2022 · Orthopaedic Surgery
  56. Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma
    Claudia Maria Hattinger, Iris C. Salaroglio, Leonardo Fantoni, Martina Godel, Chiara Casotti, Joanna Kopecka, Katia Scotlandi, Toni Ibrahim, Chiara Riganti, Massimo Serra · 2023 · International Journal of Molecular Sciences
  57. Establishment and validation of prognostic nomograms to predict overall survival and cancer-specific survival for patients with osteosarcoma
    Qiankun Yang, Qingyuan Lai, Yi Wang, Yang Wang, Zhongxiang Yao, Xiaojing Zhang · 2020 · Neoplasma
  58. Natural Killer and T Cell Infiltration in Canine Osteosarcoma: Clinical Implications and Translational Relevance
    Aryana M. Razmara, Sean James Judge, Alicia A. Gingrich, Sylvia M. Cruz, William T. N. Culp, Michael Sean Kent, Robert B. Rebhun, Robert J. Canter · 2021 · Frontiers in Veterinary Science
  59. Retracted: LINC00657 activates PD‐L1 to promote osteosarcoma metastasis via miR‐106a
    Jun Zhang, Xubin Chou, Ming Zhuang, Chenlei Zhu, Yong Hu, Dong Cheng, Zhiwei Liu · 2020 · Journal of Cellular Biochemistry · Retracted
  60. Enhancing the Potential of Immunotherapy in Paediatric Sarcomas: Breaking the Immunosuppressive Barrier with Receptor Tyrosine Kinase Inhibitors
    Emmy D.G. Fleuren, Rachael L. Terry, Déborah Meyran, Natacha Omer, Joseph A. Trapani, Michelle Haber, Paul Joseph Neeson, Paul G. Ekert · 2021 · Biomedicines
  61. PD-L1 expression in sarcomas: An immunohistochemical study and review of the literature
    Christopher R. Cunningham, Leslie G. Dodd, Magda Esebua, Lester James Layfield · 2021 · Annals of Diagnostic Pathology
  62. Immunotherapy in the Fight Against Bone Metastases: A Review of Recent Developments and Challenges
    Zhonghui Peng, Wei Ping Huang, Ziyu Xiao, Jinge Wang, Yongzhe Zhu, Fudou Zhang, Dongqiang Lan, Fengjiao He · 2024 · Current Treatment Options in Oncology
  63. Bibliometric analysis of targeted immunotherapy for osteosarcoma-current knowledge, hotspots and future perspectives
    Yunxiang Hu, Rui Yang, Shuai Ni, Zheng Song · 2025 · Frontiers in Immunology
  64. The Current Landscape of Early Drug Development for Patients with Sarcoma in the Immunotherapy Era
    Ana Sebio, Breelyn Ann Wilky, Vicki Leigh Keedy, Robin L. Jones · 2018 · Future Oncology
  65. Exosomes loaded with programmed death ligand-1 promote tumor growth by immunosuppression in osteosarcoma
    Lei Zhang, Lili Xue, Yanjuan Wu, Qilong Wu, Hongwei Ren, Xiang Song · 2021 · Bioengineered
  66. Heparin and Heparin-Based Drug Delivery Systems: Pleiotropic Molecular Effects at Multiple Drug Resistance of Osteosarcoma and Immune Cells
    Н. М. Тодосенко, Kristina Alekseevna Yurova, О. Г. Хазиахматова, Vladimir Vladimirovich Malashchenko, И. А. Хлусов, Larisa Sergeevna Litvinova · 2022 · Pharmaceutics
  67. The analysis of the pyroptosis-related genes and hub gene TP63 ceRNA axis in osteosarcoma
    Jun Han, Yunxiang Hu, Shengqiang Ding, Sanmao Liu, Hong Wang · 2022 · Frontiers in Immunology
  68. Regulatory Role of N6-methyladenosine (m6A) Modification in Osteosarcoma
    Yujie Zhang, Yanyan Wang, Liwei Ying, Sifeng Tao, Mingmin Shi, Peng Lin, Yangxin Wang, Bin Han · 2021 · Frontiers in Oncology
  69. Development of a Bioluminescent Human Osteosarcoma Model in Humanized NSG Mice: A Pilot Study
    Yunmi Ko, Yeon Ho Jeong, Jin-Hee Seo, Jun Ah Lee · 2021 · In Vivo
  70. Case report: Treatment of metastatic dedifferentiated chondrosarcoma with pembrolizumab yields sustained complete response
    Amisha Singh, Steven Walter Thorpe, Morgan Angus Darrow, Janai R. Carr · 2022 · Frontiers in Oncology
  71. Anti-GRP-R monoclonal antibody antitumor therapy against neuroblastoma
    Jingbo Qiao, Junquan Liu, Jillian C. Jacobson, Rachael A. Clark, Sora Lee, Li Liu, Zhiqiang An, Ningyan Zhang, Dai H. Chung · 2022 · PLoS ONE
  72. Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas
    Halin Bareke, Adrián Ibáñez-Navarro, Pilar Guerra‐García, Carlos González Pérez, P. Rubio, Diego Plaza López de Sabando, Ana Sastre Urgellés, Eduardo Jose Ortiz-Cruz, Antonio Pérez‐Martínez · 2023 · International Journal of Molecular Sciences
  73. Progress in immune microenvironment, immunotherapy and prognostic biomarkers in pediatric osteosarcoma
    Lin Zhang, Haoming Jiang, Hongzhi Ma · 2025 · Frontiers in Immunology
  74. Infiltration of LPAR5+ macrophages in osteosarcoma tumor microenvironment predicts better outcomes
    Yi He, Haiting Zhou, Xiaojian Huang, Yunkun Qu, Ying-Guang Wang, Wenbin Pei, Rui Zhang, Sheng Chen, Hongbo You · 2022 · Frontiers in Immunology
  75. Pseudogene MSTO2P enhances hypoxia-induced osteosarcoma malignancy by upregulating PD-L1
    Ce Shi, Chao-Ming Huang, Bing Wang, Ting-Fei Sun, Aixiang Zhu, Yu-Cheng Zhu · 2020 · Biochemical and Biophysical Research Communications
  76. Overcoming PD-1 Inhibitor Resistance with a Monoclonal Antibody to Secreted Frizzled-Related Protein 2 in Metastatic Osteosarcoma
    Patrick Nasarre, Denise I. Garcia, Julie B. Siegel, Ingrid V. Bonilla, Rupak D. Mukherjee, Eleanor Hilliard, Paramita Chakraborty, Cécile Nasarre, Jason Todd Yustein, Margaret Lang et al. · 2021 · Cancers
  77. The Dog as a Model to Study the Tumor Microenvironment
    Maria Isabel Carvalho, Teresa Pereira Raposo, Ricardo Silva-Carvalho, Isabel Cristina Ribeiro Pires, Justina Prada, Hugo Gregório, FELISBINA LUISA QUEIROGA · 2021 · Advances in experimental medicine and biology
  78. Controversies on the possible role of immune checkpoint inhibitors in pediatric cancers: balancing irAEs and efficacy
    Olga Nigro, Andrea Ferrari, Michela Casanova, Daniel H. Orbach, Amaury Leruste, Susanne A. Gatz, Didier Frappaz, Maura Massimino · 2021 · Tumori Journal
  79. Prognostic analysis of telangiectatic osteosarcoma of the extremities
    Wei Hong Zhong, Wei Luo, Zili Lin, Ziyi Wu, Yuhao Yuan, Yizhe He · 2023 · Frontiers in Oncology
  80. Osteoimmunology in bone malignancies: a symphony with evil
    Churui Song, Tie Tong, Biqi Dai, Yue Zhu, Elina Chen, Min Zhang, Weijie Zhang · 2024 · Journal of the National Cancer Center
  81. Linking Immunity with Genomics in Sarcomas: Is Genomic Complexity an Immunogenic Trigger?
    Siddh van Oost, Debora M. Meijer, Marieke L. Kuijjer, Judith V.M.G. Bovée, Noel F.C.C. de Miranda · 2021 · Biomedicines
  82. Targeting the Tumor Microenvironment of Ewing Sarcoma
    Erin Morales, Michael Olson, Fiorella Iglesias Cardenas, Tim Luetkens, Djordje Atanackovic · 2021 · Immunotherapy
  83. The perplexing role of immuno-oncology drugs in osteosarcoma
    Alannah Smrke, Yuen Bun Tam, Peter Meade Anderson, Robin L. Jones, Paul H. Huang · 2021 · Journal of bone oncology
  84. Integrative analyses of ferroptosis and immune related biomarkers and the osteosarcoma associated mechanisms
    Guibin Li, Jie Lei, Dexin Xu, Wenchang Yu, Jinping Bai, Ge Wu · 2023 · Scientific Reports
  85. Digging Through the Complexities of Immunological Approaches in Emerging Osteosarcoma Therapeutics: A Comprehensive Narrative Review with Updated Clinical Trials
    Consolato Maria Sergi, Mervin Burnett, Eugeniu Jantuan, Mariam Hakoum, Shawn T. Beug, Roger P. Leng, Fan Shen · 2025 · Biomedicines
  86. A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcoma
    Evan Rosenbaum P. E, Kenneth Seier, Martina Bradić, Sujana Movva, Ciara Marie Kelly, Mark Andrew Dickson, Mary Louise Keohan, Mrinal M. Gounder, Ping Chi, Benjamin Alexander Nacev et al. · 2025 · ESMO Open
  87. Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients
    Pinzheng Huang, Linfeng Xu, Lixi Li, Yizhong Ke, Min Zhang, Min Zhang, Kongyao Lu, Mingming Jin, Gang Huang · 2022 · Genes
  88. Dysregulation of B7 family and its association with tumor microenvironment in uveal melanoma
    Yao Chen, Anfu Zheng, Yao Zhang, Mintao Xiao, Yueshui Zhao, Xu Wu, Mingxing Li, Fukuan Du, Yu Chen, Meijuan Chen et al. · 2022 · Frontiers in Immunology
  89. Comprehensive Assessment of PD-L1 and PD-L2 Dysregulation in Gastrointestinal Cancers
    Qijie Zhao, Jinan Guo, Yueshui Zhao, Jing Shen, Parham Jabbarzadeh Kaboli, Shixin Xiang, Fukuan Du, Xu Wu, Mingxing Li, Lin Wan et al. · 2020 · Epigenomics
  90. Craniofacial Osteosarcoma—Pilot Study on the Expression of Osteobiologic Characteristics and Hypothesis on Metastasis
    Manuel Weber, Stephan Söder, Janina Sander, Jutta Ries, Carol Immanuel Geppert, Marco Rainer Kesting, Falk Wehrhan · 2020 · Frontiers in Oncology
  91. Oncolytic Viruses and Their Potential as a Therapeutic Opportunity in Osteosarcoma
    Mary Frances Wedekind, Timothy P. Cripe · 2020 · Advances in experimental medicine and biology
  92. Decoding the immune microenvironment in osteosarcoma: new insights into checkpoints, vaccines, and CAR-T cells
    Haitian Wang, Tongtong Zhu, Kunpeng Yang, Chenkai Xu, Zhaoyi Zhang, Guangyao Liu, Hongge Ren · 2025 · Frontiers in Oncology
  93. Amino acid transporter SLC7A11 functions in ferroptosis regulation and immune microenvironment in osteosarcoma
    Xueru Jia, Yangyang Shi, Jianrong Su, Yibo Zhou, Wei Li, Yajun Li, Baoshan Di, Fangyu An, Chunlu Yan · 2025 · International Immunopharmacology
  94. B7 Family Members in Pancreatic Ductal Adenocarcinoma: Attractive Targets for Cancer Immunotherapy
    Xin Chen, Jie Li, Yue Chen, Ziting Que, Jiawei Du, Jianqiong Zhang · 2022 · International Journal of Molecular Sciences
  95. Reprogramming tumor microenvironment via dual targeting co-delivery of regorafenib and alpha-difluoromethylornithine in osteosarcoma
    Hongsheng Wang, Xinmeng Jin, Ying-Hua Gao, Xin He, Yiming Xu, Haoran Mu, Yafei Jiang, Zhuoying Wang, Yu Chen, Tao Zhang et al. · 2023 · Cancer Nanotechnology
  96. New gene signature from the dominant infiltration immune cell type in osteosarcoma predicts overall survival
    Liping Gong, Xifeng Sun, Ming Jia · 2023 · Scientific Reports
  97. Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis
    Ramy Saleh, Jordan L. Scott, Nicholas Meti, Danielle Perlon, Rouhi Fazelzad, Alberto Ocaña, Eitan Amir · 2022 · Molecular Diagnosis & Therapy
  98. Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma: An Exploratory Study Related to the EORTC 90101 “CREATE” Trial
    Che‐Jui Lee, Elodie Modave, Bram Boeckx, Bernd Kasper, Steinar Aamdal, Michael Gordon Leahy, Piotr Lukasz Rutkowski, Sebastian Bauer, Maria Dêbiec‐Rychter, Raf Sciot et al. · 2022 · International Journal of Molecular Sciences
  99. Will Next-Generation Immunotherapy Overcome the Intrinsic Diversity and Low Immunogenicity of Sarcomas to Improve Clinical Benefit?
    Hui Yi Chew, Victor Chan, Fiona Simpson, Riccardo Dolcetti · 2020 · Cancers
  100. A New Signature of Sarcoma Based on the Tumor Microenvironment Benefits Prognostic Prediction
    Guanran Zhang, Aiwen Jian, Yundi Zhang, Xiaoli Zhang · 2023 · International Journal of Molecular Sciences